Long-term microdystrophin gene therapy is effective in a canine model of Duchenne muscular dystrophy

Caroline Le Guiner, Laurent Servais, Marie Montus, Thibaut Larcher, Bovdale Fraysse, Sophie Moullec, Marine Allais, Virginie François, Maeva Dutilleul, Alberto Malerba, Taeyoung Koo, Jean-Laurent Thibaut, Béatrice Matot, Marie Devaux, Johanne Le Duff, Jack-Yves Deschamps, Inès Barthelemey, Stéphane Blot, Isabelle Testault, Karim Wahbi, Stéphane Ederhy, Samia Martin, Philippe Veron, Christophe Georger, Takis Athanasopoulos, Carole Masurier, Federico Minozzi, Pierre Carlier, Bernard Gjata, Jean-Yves Hogrel, Oumeya Adjali, Fulvio Mavilio, Thomas Voit, Philippe Moullier, & George Dickson

Duchenne muscular dystrophy (DMD) is an incurable X-linked muscle-wasting disease caused by mutations in the dystrophin gene. Gene therapy using highly functional microdystrophin genes and recombinant adeno-associated virus (rAAV) vectors is an attractive strategy to treat DMD. Here we show that locoregional and systemic delivery of a rAAV2/8 vector expressing a canine microdystrophin (cMD1) is effective in restoring dystrophin expression and stabilizing clinical symptoms in studies performed on a total of 12 treated golden retriever muscular dystrophy (GRMD) dogs. Locoregional delivery induces high levels of microdystrophin expression in limb musculature and significant amelioration of histological and functional parameters. Systemic intravenous administration without immunosuppression results in significant and sustained levels of microdystrophin in skeletal muscles and reduces dystrophic symptoms for over 2 years. No toxicity or adverse immune consequences of vector administration are observed. These studies indicate safety and efficacy of systemic rAAV-cMD1 delivery in a large animal model of DMD, and pave the way towards clinical trials of rAAV-microdystrophin gene therapy in DMD patients.
Duchenne muscular dystrophy (DMD) is an X-linked inherited disease affecting ∼1/5,000 male births, leading to a highly debilitating and ultimately life-limiting muscle-wasting condition. DMD is caused by mutations in the gene coding for dystrophin, a cytoskeletal protein that is critical to the stability and function of myofibres in skeletal and cardiac muscle. Dystrophin establishes a mechanical link between the cytoskeletal actin and the extracellular matrix in muscle fibres through the dystrophin-associated protein complex, and when dystrophin is absent the mechanical and signalling functions of the costamer are compromised. DMD-affected boys develop muscle weakness during the first years of life, and although palliative treatments are available (essentially physiotherapy, assisted ventilation and glucocorticoids) they become wheelchair-bound generally before the age of 15 years. Serious, life-threatening muscle wasting and respiratory and cardiac complications arise in late teens, and patients rarely survive into their fourth decade.

Gene transfer therapy to restore dystrophin expression is considered a promising approach for the treatment of DMD. Recombinant adeno-associated virus (rAAV) vectors are particularly efficient in transducing skeletal muscle fibres and cardiomyocytes when packaged with the appropriate capsids, and allow long-term in vivo transgene expression. However, the full-length dystrophin complementary DNA (cDNA) is ∼14 kb in length and greatly exceeds the packaging capacity of a single rAAV vector. Shortened transgenes, coding for partially functional microdystrophins (MDs) that contain essential domains of the dystrophin protein, have however been generated to be compatible with rAAV vectors. The principle of using MDs as therapeutic transgenes arose from the concept that Becker muscular dystrophy patients exhibiting natural in-frame deletions/mutations in their DMD gene exhibit a milder dystrophinopathy. Several studies have shown body-wide expression and therapeutic efficacy of MDs in mdx mice following a single systemic administration of rAAV-MD vectors. In particular, a MD variant, termed MD1, was optimized for mRNA stability and translation efficiency, and packaged in rAAV vectors under the control of the synthetic muscle- and heart-specific Spc5.12 promoter. Intramuscular and systemic administration of rAAV-Spc5.12-MD1 vectors was previously shown to induce high levels of MD1 expression and complete rescue of muscle mass, specific force and resistance to eccentric contraction in mdx mice.

Intramuscular injection of a rAAV-Spc5.12-MD1 vector in a canine model of DMD resulted in sustained levels of MD1 expression in the injected muscles. The golden retriever muscular dystrophy (GRMD) model is considered a highly valuable preclinical platform to test gene therapy strategies. However, most of the published studies used immunosuppressive regimens, and were not designed to demonstrate functional improvements after treatment.

Here, we show for the first time the long-term therapeutic potential of locoregional (LR) and systemic intravenous (IV) administration of rAAV2/8-Spc12-cMD1 vector in GRMD dogs, in the absence of any immunosuppression. Both procedures are well tolerated, and expression of the canine MD1 (cMD1) significantly reduces the physiological decline in muscle strength of treated limbs and stabilizes clinical parameters in the treated animals, in the absence of toxicity and of deleterious humoral or cell-mediated immune responses against the transgene product. Importantly, gene expression and clinical benefit are sustained over time, up to 24 months after vector injection. This study, carried out in a large animal model of DMD, paves the way to clinical translation of rAAV-MD1 gene therapy in DMD patients.

Results

Study design. We tested the administration of a rAAV2/8 vector encoding a sequence-optimized cMD1 cDNA driven by the synthetic muscle- and heart-specific Spc5.12 promoter (rAAV2/8-Spc5.12-cMD1) injected via LR or systemic IV routes in male GRMD dogs. The study design is summarized in Table 1. First, four GRMD dogs (3.5 to 4 months old) were injected in one forelimb via LR transvenous infusion as previously described, using a single administration of 1 × 10^13 vector genome (vg) kg⁻¹ of the therapeutic vector. The contralateral untreated forelimb in the LR-treated dogs acted as controls, and three control GRMD dogs were also included and received the vehicle only (Table 1). Age-matched wild-type (WT) animals were also enrolled as additional controls for nuclear magnetic resonance (NMR) and muscle strength evaluations. We set the total injected volume at 20% of the limb volume to match the injection protocol recently reported in patients with neuromuscular diseases.

Injected dogs were followed for 3 months and then euthanised. In a second part of the study, eight GRMD dogs (2 to 2.5 months old) were treated systemically by peripheral vein injection with two different doses of the therapeutic vector: the first group of 5 dogs (IV-A) received a single dose of 1 × 10^14 vg kg⁻¹ of rAAV2/8-Spc5.12-cMD1 while the second group of 3 dogs (IV-B) received a single lower dose of 2 × 10^13 vg kg⁻¹ (Table 1). At the time of manuscript submission, we were able to follow 2 high-dose individuals (dogs IV1 and IV2) up to 2 years after vector injection and the 6 other individuals ∼8 months after therapy. Nine supplemental untreated GRMD dogs were also included and followed in parallel of these IV-treated dogs (Table 1), and supplemental healthy dogs were also used as controls. Importantly, no animal received immunosuppression at any stage, and they were randomized to the different groups (group IV-A, group IV-B or controls IV) with no phenotypic selection. It should be noted however that the appearance of severe muscle weakness, dysphagia and respiratory abnormalities before the age of 2 months (which occur in <5% of the global number of GRMD dogs of our colony) were considered as exclusion criteria for the study. Animals and biopsy samples were recoded in neutral fashion, and functional, histological and molecular analyses were performed in a blinded manner for both the LR and the systemic treatment studies.

rAAV2/8-Spc5.12-cMD1 vector has good safety profile. Administration of rAAV2/8-Spc5.12-cMD1, both LR and systemic, was uneventful in all animals. Blood tests including electrolytes, kidney and liver function parameters and complete haematology counts remained unchanged in the hours, days and weeks after vector delivery (Supplementary Data 1 and 2). No evidence of vector-induced toxicity was observed in any of the treated dogs. Of note, dog IV3 suffered a treatment-unrelated accidental fracture of the left forelimb ~2 months after rAAV injection. This fracture was surgically repaired and the dog entirely recovered his motor ability at <2 months after the accident. Overall, the rAAV2/8-Spc5.12-cMD1 showed an excellent safety profile in both LR and systemically treated animals at any injected dose.

Efficient cMD1 expression after LR administration. The four LR-injected dogs were euthanised 3 months after vector injection. Skeletal muscles of each forelimb, as well as skeletal muscles at distance (total of 46 muscles) and several major organs were sampled after killing and used to evaluate cMD1 expression and vector genome copies per diploid genome (vg dg⁻¹). cMD1 expression was evaluated by both immunoperoxidase staining and western blot. Figure 1a shows representative staining
results in cycles of muscle degeneration and regeneration that of dystrophin protein in both DMD patients and GRMD dogs. Expression of cMD1 improves muscle histopathology (Fig. 1).

| Group | Dog | Mode of delivery | Injected product and dose | Injected rAAV batch | Age at inclusion/ injection | Follow-up duration after inclusion/injection |
|-------|-----|------------------|---------------------------|---------------------|-----------------------------|------------------------------------------|
| LR    | LR1 | Locoregional     | rAAV2/8-Spc5.12- cMD1     | A.12005.PSR         | 4 Months                    | 3 Months                                 |
| LR    | LR2 | Transvenous      | 1 × 10^{13} vg kg^{-1}    | A.12005.PSR         | 4 Months                    | 3 Months                                 |
| LR    | LR3 | Perfusion        |                           | A.12005.PSR         | 3.5 Months                  | 3 Months                                 |
| LR    | LR4 | Perfusion        |                           | A.12005.PSR         | 3.5 Months                  | 3 Months                                 |
| Controls | LR C1 | Locoregional  | Buffer                    | NA                  | 3.5 Months                  | 3 Months                                 |
| Controls | LR C2 | Locoregional  | Buffer                    | NA                  | 4 Months                    | 3 Months                                 |
| Controls | LR C3 | Locoregional  | Buffer                    | NA                  | 3.5 Months                  | 3 Months                                 |
| Group IV-A | IV1 | Intravenous | rAAV2/8-Spc5.12- cMD1     | A.12005.PSR         | 2 Months                    | 24 Months                                |
| Group IV-A | IV2 | Intravenous | 1 × 10^{14} vg kg^{-1}    | A.12005.PSR         | 2.5 Months                  | 24 Months                                |
| Group IV-A | IV3 | Intravenous |                           | A.12005.PSR         | 2 Months                    | 7.5 Months                                |
| Group IV-A | IV4 | Intravenous |                           | A.12005.PSR         | 2.5 Months                  | 8.5 Months                                |
| Group IV-A | IV5 | Intravenous |                           | A.12005.PSR         | 2 Months                    | 8 Months                                 |
| Controls | IV C1 | NA              | NA                       | NA                  | 1.5 Months                  | 3 Months                                 |
| Controls | IV C2 | (untreated)   | NA                       | NA                  | 3 Months                    | 4.5 Months                                |
| Controls | IV C3 | NA              | NA                       | NA                  | 3 Months                    | 4.5 Months                                |
| Controls | IV C4 | NA              | NA                       | NA                  | 3.5 Months                  | 9 Months                                 |
| Controls | IV C5 | NA              | NA                       | NA                  | 3 Months                    | 4 Months                                 |
| Controls | IV C6 | NA              | NA                       | NA                  | 3 Months                    | 23 Months                                |
| Controls | IV C7 | NA              | NA                       | NA                  | 2 Months                    | 3 Months                                 |
| Controls | IV C8 | NA              | NA                       | NA                  | 2.5 Months                  | 4.5 Months                                |
| Controls | IV C9 | NA              | NA                       | NA                  | 2 Months                    | 7 Months                                 |

NA, not applicable.

*At 2 months post injection, accidental fracture of the left forelimb.

obtained in different muscles of dog LR1, sampled in the non-injected and injected forelimbs, below or above the tourniquet used to isolate the limb during the injection. MD1 was consistently expressed at high levels in muscle groups of the transduced forelimb, averaging 51%, 59%, 49% and 43% cMD1-positive fibres in dogs LR1 to LR4, respectively (Table 2). As observed in a previous study with a different rAAV2/8 vector35, shedding of the vector after release of the tourniquet also induced significant transduction in the contralateral limb and in distant muscle groups, with an average of 10%, 10%, 11% and 7% cMD1-positive fibres in dogs LR1 to LR4, respectively. In particular, significant transduction was observed in the diaphragm of dogs LR1 and LR3, with 13% and 18% of cMD1-positive fibres, respectively (Table 2). Immunolabelling data correlated proportionately with the detection of the ~138 kDa cMD1 protein band by western-blot analysis (Fig. 1b) and of the cMD1 mRNA by reverse transcription quantitative PCR (RT-Q-PCR) in the same skeletal muscles samples (Supplementary Fig. 1). As shown in Supplementary Fig. 2, the percentage of cMD1-positive fibres and vector copy numbers, determined by Q-PCR analysis on the same muscle samples of the injected limbs, led to the direct correlation of ~50% of cMD1-positive fibres being detected with the presence of 1 vg dg^{-1}. Only low levels of cMD1 mRNA were detected in major organs (liver, spleen and lymph nodes) despite the presence of high vg dg^{-1} values, confirming the muscle-restricted activity of the Spc5.12 promoter (Supplementary Fig. 1).

Expression of cMD1 improves muscle histopathology. Absence of dystrophin protein in both DMD patients and GRMD dogs results in cycles of muscle degeneration and regeneration that over time cause muscle tissue remodelling and replacement of muscle fibres by fibrotic tissue36,37. To investigate the effect of cMD1 expression on muscle pathology, we compared muscle regeneration and fibrosis in extensor carpi radialis and flexor carpi ulnaris muscles, sampled at the time of killing in both injected and noninjected forelimbs of each GRMD dog injected by the LR route either with the rAAV2/8-Spc5.12-cMD1 vector (n = 4 dogs) or with buffer (n = 3 dogs). In the four treated dogs, myofibre turnover (regeneration) and collagen deposition (fibrosis) were reduced in muscles of injected limbs compared with contralateral limbs (Fig. 2a). Since muscles of the noninjected limb were also transduced, although to a lesser extent, we correlated histological improvements with gene transfer efficiency, clustering the muscles in 3 groups based on the percentage of cMD1-positive fibres (that is, ≤12%, between 13 and 45% and between 46 and 90%). Muscles of treated limbs exhibiting >46% of cMD1-positive fibres showed a trend towards a decrease in myofibre regeneration and of endomysial fibrosis (Fig. 2b). In addition, a significant decrease of total fibrosis was observed in muscles harbouring >46% of cMD1-positive fibres compared with muscles with ≤12% of cMD1-positive fibres (P < 0.05, Kruskal–Wallis test, Fig. 2b).

Proton 1H-NMR imaging and phosphorous 31P-NMR spectroscopy analysis of treated and untreated forelimbs were performed just before killing in two dogs, LR1 and LR2. Dogs LR3 and LR4 were considered ineligible for the anaesthesia required for the exam due to a treatment-unrelated bronchopneumonia and were excluded from this analysis. The most relevant 1H-NMR imaging indices, relying on T2, T1 and proton density-weighted image signal intensities (T2w, T1w, proton density (PD))38, were calculated on three different muscles (extensor carpi radialis brevis, extensor carpi radialis longus and flexor carpi ulnaris). In

Table 1 | Characteristics of the different GRMD dogs of this study.

| Group | Dog | Mode of delivery | Injected product and dose | Injected rAAV batch | Age at inclusion/ injection | Follow-up duration after inclusion/injection |
|-------|-----|------------------|---------------------------|---------------------|-----------------------------|------------------------------------------|
| IV-A  | IV1 | Intravenous     | rAAV2/8-Spc5.12- cMD1     | A.12005.PSR         | 2 Months                    | 8.5 Months                                |
| IV-A  | IV2 | Intravenous     | 1 × 10^{14} vg kg^{-1}    | A.12005.PSR         | 2.5 Months                  | 8.5 Months                                |
| IV-A  | IV3 | Intravenous     |                           | A.12005.PSR         | 2 Months                    | 8.5 Months                                |
| IV-A  | IV4 | Intravenous     |                           | A.12005.PSR         | 2.5 Months                  | 8.5 Months                                |
| IV-A  | IV5 | Intravenous     |                           | 14D0332            | 2.5 Months                  | 6.5 Months                                |
| Controls | IV C1 | NA              | NA                       | NA                  | 1.5 Months                  | 3 Months                                 |
| Controls | IV C2 | (untreated)     | NA                       | NA                  | 3 Months                    | 4.5 Months                                |
| Controls | IV C3 | NA              | NA                       | NA                  | 3 Months                    | 4.5 Months                                |
| Controls | IV C4 | NA              | NA                       | NA                  | 3.5 Months                  | 9 Months                                 |
| Controls | IV C5 | NA              | NA                       | NA                  | 3 Months                    | 4 Months                                 |
| Controls | IV C6 | NA              | NA                       | NA                  | 3 Months                    | 23 Months                                |
| Controls | IV C7 | NA              | NA                       | NA                  | 2 Months                    | 3 Months                                 |
| Controls | IV C8 | NA              | NA                       | NA                  | 2.5 Months                  | 4.5 Months                                |
| Controls | IV C9 | NA              | NA                       | NA                  | 2 Months                    | 7 Months                                 |


Figure 1 | Analysis of cMD1 expression by immunostaining and western-blot in muscles of GRMD dogs injected with rAAV2/8-Spc5.12-cMD1 by the LR route. (a) Dystrophin immunostaining (NCL-DYSB) on transverse sections of muscle samples. Representative results are presented for healthy (WT) and untreated GRMD dogs and for four different muscles of dog LR1 sampled at the time of killing (non injected and injected forelimb, below and above the tourniquet). Scale bar, 100 μm. (b) Western-blot analysis of total proteins (50 μg) extracted from muscles samples. Representative results for the same muscles as in a are shown. GRMD myoblasts transduced with the rAAV2/8-Spc5.12-cMD1 vector were used as positive control. The blot was stained with MANEX-1011C to reveal the presence of the 427 kDa dystrophin protein (WT dog) and the 138 kDa cMD1 protein, with an anti-GAPDH antibody as a loading control. The level of cMD1-positive fibres detected by immunostaining from the same muscle samples are indicated under each panel.

31P spectroscopy, signals were measured from the two extensor carpi radialis muscles. Visual assessment of 1H-NMR images in the muscles of the two analysed dogs showed altered magnetic resonance properties indicating a reduction of edema, inflammation, necrosis and cell damage. Indeed, muscle signals were less hyperintense on T2-weighted images and more homogeneous within and between muscles (Fig. 3a). We also observed a reversion in abnormal levels of phosphocreatine, inorganic phosphate and phosphodiesters in 31P-NMR spectra in the injected forelimbs of treated dogs, reflecting improved sarcolemmal membrane stability and muscle tissue metabolism (Fig. 3b). Finally, most imaging indices showed an improvement in the injected compared with the noninjected forelimbs, with a decrease of the fat-saturated T2w/T1w 1H-NMR imaging index, and the 31P-NMR spectroscopic Pi/γATP index to levels close to or within normal ranges of healthy dogs (Fig. 3c,d). Taken together, histology, NMR imaging and spectroscopy analysis confirmed a significant reduction of the dystrophic pathology in muscles of forelimbs injected with the rAAV2/8-Spc5.12-cMD1 vector.
Expression of cMD1 improves muscle strength. The effect of cMD1 expression on the functionality of the injected forelimb of all the LR-treated dogs was evaluated by measuring the extension strength of the wrist. We evaluated both forelimbs of the 4 injected GRMD dogs before LR treatment at 45 and at 90 days after buffer or rAAV2/8-Spc5.12-cMD1 injection. Seven age-matched WT golden retriever dogs were also evaluated in both forelimbs. At each time point, the maximal torque was measured and normalized by the animal’s weight. As shown in Fig. 4a, a clear difference was observed between the extension strength in forelimbs of WT and of untreated GRMD animals. Injection of rAAV2/8-Spc5.12-cMD1 significantly improved the muscle extension strength in the injected forelimbs compared with the noninjected ones as well as with those of untreated GRMD dogs, and normalized the values to the WT level at day +90. In the treated animals, the extension strength change between day 0 (before injection) and day +90 was significantly higher in the injected forelimb than in the noninjected forelimb (P < 0.05, Kruskal–Wallis test, Fig. 4b). These results highlight the functionality of cMD1 in maintaining and eventually increasing muscle strength in dystrophin-deficient treated limbs.

Body-wide expression of cMD1 improves pathology in GRMD dogs. Prompted by the encouraging results obtained in the LR delivery study, we then systemically administered the rAAV2/8-Spc5.12-cMD1 vector by a single intravenous injection in two groups of GRMD dogs: the first (IV-A, high dose, n = 5) received a dose of 1 × 10^{14} vg kg^{-1} and the second (IV-B, low dose, n = 3) received a dose of 2 × 10^{13} vg kg^{-1}. The age of the animals at treatment was ~2 months (Table 1). We report here the ongoing follow-up of the IV-injected animals for more than 2 years post vector administration in two dogs (dogs IV1–2) and at ~7 to 8 months post injection in six further dogs (dogs IV3–8). Surgical biopsies were performed in different skeletal muscles before the treatment, and at 3.5, 8 and 14 months after vector injection. Representative cMD1 immunostaining and western-blot of several skeletal muscle biopsy specimens obtained from IV-A- and IV-B-treated GRMD dogs are presented in Fig. 5. Levels of cMD1-positive fibres and vg dg^{-1} values are plotted in Supplementary Fig. 3. All dogs in the IV-A group (high dose) exhibited significant levels of cMD1-positive fibres (20 to 80%) and vector transduction levels between 1 and 6 vg dg^{-1} in the various muscular biopsies. As an example, dog IV2 showed in the different biopsied muscles an average of 67%, 57% and 40% cMD1-positive fibres, respectively at 3.5, 8 and 14 months post injection, with vector copy numbers around 4, 1 and 1 vg dg^{-1} in the same muscle samples (Fig. 5a and Supplementary Fig. 3). As muscles were biopsied at different time points, and as tissue transduction could be heterogeneous even within a same muscle, we cannot stringently compare these data overtime. However, a clear and statistically significant (P < 0.001 or 0.01, Mann–Whitney test) dose reduction effect was observed in dogs of the IV-B group (low dose) that showed on average <10% of cMD1-positive fibres and no more than 0.1 vg dg^{-1} observed in muscle biopsies obtained at 3.5 and 8 months post injection (Supplementary Fig. 3). Immunolabelling and vg dg^{-1} data correlated proportionately with the detection of the ~138 kDa cMD1 protein band by western-blot analysis. Of note, the levels of cMD1 protein detected in some skeletal muscles of dogs of the IV-A group reached at least 50% of the normal level of native dystrophin found in WT dogs (Fig. 5b). Regeneration and total fibrosis were also evaluated in muscle biopsies obtained at 3.5 months post injection and showed a significant correlation with the levels of cMD1-positive fibres, as observed in the LR administration study (Supplementary Fig. 4).

Overall, these data indicate that systemic delivery of rAAV2/8-Spc5.12 results in generalized and stable skeletal muscle transduction and cMD1 expression, accompanied by a significant attenuation of the dystrophic pathology in GRMD dogs.

### Table 2 | Levels of cMD1-positives fibres found after immunostaining analysis (NCL-DYSB) within the muscles of GRMD dogs injected by the LR route.

| Dog | Injected forelimb (n = 13 muscles) | Noninjected forelimb (n = 13 muscles) | Other muscles at distance (n = 17 muscles) | Heart | Diaphragm |
|-----|-----------------------------------|--------------------------------------|------------------------------------------|-------|----------|
|     | Mean of cMD1+ fibres CV Mean of cMD1+ fibres for the group CV | Mean of cMD1+ fibres Mean of cMD1+ fibres Mean of cMD1+ fibres | Mean of cMD1+ fibres Mean of cMD1+ fibres Mean of cMD1+ fibres |
| LR1 | 51% 54% 50% 47% | 3% 10% <0.5% 13% | |
| LR2 | 59% 30% | 1% 10% <0.5% <0.5% | |
| LR3 | 49% 58% | 3% 11% <0.5% 18% | |
| LR4 | 43% 49% | 1% 7% <0.5% 1% | |
| LR C1 | <0.5% NA <0.5% NA | <0.5% <0.5% <0.5% | |
| LR C2 | <0.5% NA | <0.5% <0.5% <0.5% | |
| LR C3 | <0.5% NA | <0.5% <0.5% <0.5% | |

CV, coefficient of variation.
For the complete list of muscles and tissues sampled at the time of killing, see Supplementary Table 2 in ref. 33.
untreated GRMD dogs were subjected to veterinarian-instructed killing. Indeed, even if a lifespan of ~3 years was described in some GRMD colonies26, most untreated GRMD dogs of our colony show a rapid disease progression down to a clinical score of 30% at ~1 year of age with death rapidly occurring after this point. A certain degree of variability among dogs may be observed, as previously reported26 and as observed in our study with in particular one untreated control animal (out of the 9 included in the study—dog IV C6) stabilized at a clinical score of ~50% up to 26 months of age (Fig. 6a). Dogs in the high-dose group progressed much less rapidly than the majority of the untreated GRMD dogs, stabilizing in two cases at >50% (IV1) and >80% (IV2) at >2 years of age. Of note, even if dog IV1 exhibited the same clinical score (>50%) than one of the untreated GRMD dogs (dog IV C6), histological evaluations of muscle biopsies performed at 2 years of age in these 2 dogs showed a clear difference between these 2 animals in terms of pathological muscular pattern, with dystrophic features being numerous in the muscles of the untreated GRMD dog but highly reduced in the muscles of dog IV1 (Supplementary Fig. 5).

Moreover, statistical evaluation of clinical scores at the 6 and 9 months time point showed significantly (P < 0.01, Kruskal–Wallis test) higher scores in high-dose treated animals compared with untreated control animals (Fig. 6b). Notably, among the clinical parameters evaluated, the mean age of appearance of the characteristic dysfunctions in digestive (dysphagia) and respiratory (abdominal breathing) activities was substantially delayed in the high-dose group (Supplementary Table 1). Of note, none of our GRMD dogs (treated or untreated) carried the recently described mutation in the Jagged1 gene (Supplementary Fig. 6) that can be responsible for a milder phenotype and a normal lifespan in GRMD dogs despite the complete absence of dystrophin44.

In addition to clinical score parameters, we objectively evaluated the gait quality of the dogs on a bimonthly basis using the previously described Locometrix system42,43. For this study supplemental retrospective control data were assembled from groups of WT golden retrievers and untreated GRMD dogs. Figure 7 shows the evolution of the mean global gait index with 95% confidence intervals in healthy control dogs, untreated GRMD dogs and GRMD dogs injected systemically with rAAV2/8-Spc5.12-cMD1 at low dose or at high dose up to ~7 months post injection. Dogs in the IV-A group showed a significantly higher gait index compared with untreated GRMD dogs, and an evolution towards a pattern very close to that of the wild-type golden retriever dogs. IV1 and IV2 dogs were evaluated until ~1.5 year after injection and maintained a stable gait score (Supplementary Fig. 7). In line with the evolution of their clinical

Figure 2 | Improvement of pathological pattern in the cMD1-expressing muscles. After killing, two muscles (the flexor carpi ulnaris muscle and the extensor carpi radialis muscle) in each forelimb of each GRMD dog injected by the LR route either with the rAAV2/8-Spc5.12-cMD1 vector (n = 4 dogs and 16 muscles analysed) or with buffer (n = 3 dogs and 12 muscles analysed) were analysed. Myofibre regeneration was evaluated by immunohistochemical staining of myofibres using an antibody specific for developmental myosin heavy chain isoform. Total and endomysial fibrosis were evaluated by immunohistochemical detection of Collagen I. (a) Regeneration and fibrosis immunostaining on transverse sections of muscle samples. Representative results are presented for two muscles of dog LR1 (noninjected forelimb and injected forelimb). The levels of cMD1-positive fibres detected by immunostaining from the same muscle samples are indicated above each panel. Scale bar, 100 µm. (b) Regeneration, total fibrosis and endomysial fibrosis quantification in the total of 28 muscles analysed in the GRMD dogs injected by the LR route, either with the rAAV2/8-Spc5.12-cMD1 vector or with buffer was done using an automatic measurement of the percentage of the labelled area after selection of regions of interest. Analyses were done according to the percentage of cMD1-positive fibres of each muscle: <12% (n = 20, empty symbols), between 30 and 45% (n = 4, grey full symbols) and between 46 and 90% (n = 4, black full symbols). Each point represents the data obtained in one muscle, and the horizontal bars represent the mean of the values obtained for each group *P < 0.05 (nonparametric Kruskal–Wallis test with post hoc multiple comparison Dunn’s test).
score, dogs of the IV-B group showed a transient improvement of the gait index that was not maintained at later time points (Fig. 7).

These data demonstrate that systemic delivery of rAAV2/8-Spc5.12-cMD1 substantially ameliorates the clinical manifestations and improves gait parameters of GRMD dogs.

**Evaluation of immune responses after vector delivery.** We monitored humoral (presence of immunoglobulin G (IgG) antibodies in the serum) and cellular (specific interferon-γ (IFN-γ) secretion from peripheral blood mononuclear cells (PBMCs)) immune responses against the cMD1 protein in the GRMD dogs injected by LR or systemic IV route of administration (Table 3). We detected a transient humoral response against the cMD1 protein as soon as 1 or 2 months post injection in 3 out of 4 LR-injected and in 3 out of 8 IV-injected dogs, the latter all being injected with the high vector dose. In all dogs, anti-cMD1 IgG appear between 1 and 2 months after vector injection and then declined to undetectable levels at 8 months after vector injection.
(except for the IV4 dog for which IgG were still detectable at this time point—Table 3) without obvious or gross deleterious consequences. The transient nature of the anti-MD1 humoral immune response is shown as an example for the IV2 dog in Supplementary Fig. 8. T-cell responses directed against the cMD1 protein were assessed by IFN-γ enzyme-linked immunospot (ELISPOT) using stimulated PBMCs collected at different time points post injection. None of the injected dogs exhibited detectable levels of IFN-γ response above the threshold of positivity at any time point (Table 3). Dogs IV1 and IV2 maintained negative IgG and IFN-γ responses up to 2 years after injection (Table 3). We analysed anti-AAV8 capsid humoral and cellular immune responses in the four dogs injected via the LR route. As expected, and in line with previous studies33, we detected elevated and persistent IgG and neutralizing antibody levels to the AAV8 capsid in the serum of the four injected dogs (Supplementary Fig. 9), but no anti-capsid reactive T cells as measured by IFN-γ ELISPOT (Supplementary Table 2).

Overall, these data suggest that LR or systemic administrations of rAAV2/8-Spc5.12-cMD1 vector elicit no detrimental humoral or cytotoxic immune responses in GRMD dogs despite the lack of immunosuppression.

Discussion

Here, we show for the first time the effective, long-term and safe delivery of a microdystrophin transgene in the GRMD dog model of DMD by both LR and systemic administration of a rAAV2/8 vector and in the absence of preventive immunosuppression. In both studies, we utilized a sequence-optimized MD1 gene under the control of a skeletal muscle and heart-specific transcriptional regulatory element delivered in ‘GMP-like’ grade rAAV2/8 vectors. We initially tested the LR delivery of rAAV2/8-Spc5.12-cMD1 and observed high levels of cMD1+ fibres, averaging 50% in the muscles of the treated limb. These data correlated with cMD1 expression levels detected by western blot and RT-Q-PCR mRNA assays. Overall, high-level expression of the optimized cMD1 cassette combined with a LR route of delivery was associated with significant histological and functional amelioration in the injected limb, despite the reduced size of the protein and the absence of known functional domains, such as the neuronal nitric oxide synthase binding and relocalization domain44.

To our knowledge this is the first time a gene therapy based on rAAV-MD gene delivery by LR isolated limb perfusion and without immunosuppression has been performed in young adult GRMD dogs, showing clear prevention of degeneration/regeneration, fibrosis, magnetic resonance imaging and NMR changes and loss in muscle strength.

We and others previously showed the successful implementation of the LR delivery route by administration to GRMD dogs of rAAV2/8 vectors expressing exon-skipping antisense RNA sequences under the control of the U7snRNA promoter (rAAV2/8-U7snRNA-E6/E8)33,45. Interestingly, while both vectors were manufactured using an identical protocol, expression of a microdystrophin protein from the rAAV2/8-Spc5.12-cMD1 vector restored a higher number of phenotypically corrected fibres at comparable vg dg⁻¹ values with respect to the exon-skipping vector that restores the synthesis of an almost full-length dystrophin protein. This may be explained by the stronger activity of the synthetic Spc5.12 promoter or by the overall higher efficiency of a gene replacement (one step event) compared with the splicing correction approach (two-step event).

We next evaluated the therapeutic effect of rAAV2/8-Spc5.12-cMD1 vector after systemic transvenous delivery in juvenile GRMD dogs, again in the absence of immunosuppression. We focused our investigations on relevant clinical outcomes, similarly to what would be applied in a phase I/II clinical trial in DMD.
Figure 5 | Analysis of cMD1 expression by immunostaining and western-blot in muscular biopsies of GRMD dogs injected with rAAV2/8-Spc512-cMD1 by the IV route. (a–c) Dystrophin immunostaining (NCL-DYSB) on transverse sections of muscle samples. Representative results are presented for two treated GRMD dogs injected with different doses of the rAAV2/8-Spc5.12-cMD1 vector by the IV route: dog IV2, injected with \(1 \times 10^{14} \text{vg kg}^{-1}\) (a) and dog IV7, injected with \(2 \times 10^{13} \text{vg kg}^{-1}\) (b). A healthy (WT) dog is also presented as control (c). For the treated dogs, different muscle samples were obtained after surgical biopsies performed before injection, at 3.5 months post injection, at 8 months post injection and at 14 months post injection (only for Dog IV2 for this latter time point). The level of cMD1-positive fibres is indicated above each panel, as well as the number of vector genomes per diploid genomes detected by qPCR in the same muscle sample. Scale bar, 100 μm. (d) Western blot analysis of total proteins (50 μg) extracted from muscles samples. Representative results are presented for two other treated GRMD dogs, injected with different doses of the rAAV2/8-Spc5.12-cMD1 vector by the IV route: dog IV4, injected with \(1 \times 10^{14} \text{vg kg}^{-1}\) and dog IV6, injected with \(2 \times 10^{13} \text{vg kg}^{-1}\). Then, 50 μg of total proteins extracted from GRMD myoblasts transduced with the rAAV2/8-Spc5.12-cMD1 vector were used as positive control, as well as 25 to 75 μg of total proteins extracted from a skeletal muscle of a WT dog. The blot was stained with MANEX-1011C to reveal the presence of the 427 kDa dystrophin protein (WT dog) and the 138 kDa cMD1 protein, with an anti-GAPDH antibody as a loading control. The level of cMD1-positive fibres detected by immunostaining as well as the number of vector genomes per diploid genomes detected by qPCR from the same muscle samples are indicated under each panel.
patients. These included evaluation of the clinical status as well as of the gait of the animals, while biodistribution and expression of the transgene analyses were limited to iterative muscle biopsies over time. We observed a dose-dependent and significant stabilization, even improvement, of clinical parameters and of gait scores, with $10^{13}$ vg kg$^{-1}$ being under-dosed, whereas $10^{14}$ vg kg$^{-1}$ was effective, but still presenting heterogeneity among treated dogs. Nevertheless, this is the first demonstration of a long-term generalized clinical improvement of ‘Jagged1-negative’ GRMD dogs (up to 2 years of age for 2 dogs at the time of manuscript submission) after systemic administration of a rAAV2/8-MD vector. Unfortunately, since the emergence of cardiac pathology is very rare and with a late onset (over 1 year of age) in the untreated GRMD dogs of our colony, we have been unable to evaluate the impact of MD1 gene therapy on the cardiac function of the treated GRMD dogs by using conventional echocardiography, two-dimensional (2D) colour tissue Doppler imaging or even speckle tracking imaging (Supplementary Fig. 10). The recently described DMD$^{mdx}$ rat model, which presents cardiac hypertrophy followed by a dilated cardiomyopathy similar to the one observed in DMD patients, should allow a better evaluation of the impact of rAAV2/8-Spc5.12-MD1 treatment on the dystrophin-deficient cardiac pathology.

Only a handful of studies addressed so far the issue of bodywide systemic gene therapy in dystrophic dogs. A rAAV2/9 vector carrying a human sequence-optimized microdystrophin construct driven by the ubiquitous cytomegalovirus (CMV) promoter was injected intravenously in three 4-day-old dystrophic dog neonates. In this study, the early inflammatory side effects observed in the pelvic region were likely linked to the use of the ubiquitous CMV promoter and/or to the expression of a non-species-specific human protein that may have induced a strong immune response in the muscles. No immune suppression was used in these dogs as animals treated soon after birth were expected to mount a less robust response due to the relatively immature nature of their immune system. In another study, dystrophic dog fetuses were transduced intra-amniotically to
Figure 7 | Improved gait quality of GRMD dogs injected with rAAV2/8-Spc5.12-cMD1 by the IV route. The global gait quality was determined twice a month using Locometrix and analysed by a discriminant analysis of seven accelerometric variables. The curves represent the evolution of the mean gait index with 95% confidence intervals (shaded areas) in healthy dogs (n = 9, including animals from retrospective cohorts, green curve), untreated GRMD dogs (n = 25, including animals from retrospective cohorts, red curve) and GRMD dogs injected intravenously with rAAV2/8-Spc5.12-cMD1 at $2 \times 10^{13}$ vg kg$^{-1}$ (n = 3, light grey curve) or $1 \times 10^{14}$ vg kg$^{-1}$ (n = 5, dark grey curve). F1 and F2 represent the two axes used to plot data during discriminant analysis. An additional axis corresponding to the age in months was also calculated and represented. The discriminant analysis (see details in the Methods section) allows a statistical evaluation to test the probability that the gait of the treated animals was similar (P > 0.95) to those of healthy dogs or of untreated GRMD dogs. The result of this statistical evaluation was represented as a colour code, using a green plot when the gait was found similar to those of healthy dogs, a red plot when similar to those of untreated GRMD dogs and yellow when the gait was considered as intermediate between healthy and untreated GRMD dogs.

investigate the therapeutic effects of a rAAV vector expressing microdystrophin under conditions of immune tolerance. At 6 weeks after birth, rAAV2/9-CMV-microdystrophin was reinjected into the jugular vein of one of the dystrophic dog to induce systemic expression of MD. Gait and cardiac function improvement was observed in the treated dogs, suggesting that administration of a rAAV-microdystrophin vector after in utero tolerization could induce successful long-term transgene expression. A recent study in two 2-month-old DMD dogs used a tyrosine engineered modified rAAV9 capsid as the vehicle to deliver a canine sequence-optimized flag-tagged microdystrophin construct driven by a CMV promoter. Animals were euthanised at 4 months post injection, and sustained immunosuppression (cyclosporine A + mycophenolate mofetil) was applied. Although high doses (up to $5\times6 \times 10^{14}$ vg kg$^{-1}$) were systemically injected, an average of only 25% of MD-positive fibres were found in this limited cohort and no functional or histopathological improvements were reported.

Unlike rodents, dog immunity shares many common features with its human counterpart with a full development before birth, although the maturity of the immune system completes after birth. An important observation of our study, in view of clinical translation, was the lack of systemic adverse effects and anti-cMD1 T-cell immune responses at the highest, efficacious dose of cMD1 vector, associated with long-term persisting transgene expression despite the occasional and transient detection of anti-cMD1 IgGs in most of the dogs. Importantly, the transient humoral immune response was apparently without serious consequences in the transduced muscles or in peripheral organs. In fact, the detection of humoral immunity against a transgene product is not systematically associated with immunotoxicity in gene therapy protocols. The same type of non-deleterious humoral immune response has already been shown in haemophilia dogs following LR rAAV vector delivery without affecting factor IX transgene expression in animals. This lack of deleterious adverse inflammatory and immunological reactions to the cMD1 transgene product may be due to several factors. Unlike intramuscular injection, LR and systemic transvenous infusion routes are associated with a lack of immunotoxicity as previously described for other transgenes. It was also previously demonstrated in a mouse model of limb-girdle muscular dystrophy-2D that the use of a muscle-specific synthetic promoter, such as the Spc5.12 promoter used to restrict transgene expression in the present study, can lead to long-lasting transgene expression, whereas immune rejection was observed when the transgene is driven by the ubiquitous CMV promoter. Furthermore, the presence of natural dystrophin ‘revertant fibres’ in GRMD dogs (as in the majority of DMD patients) could be a powerful tolerogenic factor. Moreover, while we did observe a humoral (IgM, IgG and NAB) immune response to AAV8 capsid in the treated dogs, there was no detectable cellular immune response against proteins of the AAV8 capsid, in line with our previous studies. The lack of detectable T-cell responses may be the result of rAAV/8 vector produced in GMP (good manufacturing practices)-compliant baculovirus-insect Sf9 cell factories that may be effective in tackling adjuvant or proinflammatory effects of vector-associated or mammalian cell by-products observed in rAAV lots generated by standard co-transfection protocols in 293 cells. However, it is important to note that in current and ongoing rAAV vector gene therapy trials in humans, low-level and variable transient hepatotoxicity has been reported to be associated with cellular immune responses to AAV components and to be controlled by corticosteroid immunosuppression. In the case of DMD, corticosteroid therapy has become the standard of care. It is thus likely that any future MD gene therapy clinical trial will recruit patients already taking and continuing to take corticosteroids, and thus already immunosuppressed. We would also point out that seropositivity to AAV8 arising from exposure to WT AAV8 virus or to a recombinant gene delivery vector will most likely preclude subjects from subsequent rAAV8-mediated gene therapy. Powerful physical (for example, plasmapheresis) and/or drug-induced immunosuppressive regimens are being investigated to potentially enable administration of rAAV gene therapy vectors in the presence of preexisting AAV antibodies.

In conclusion, our data support the overall safety and therapeutic efficacy in GRMD dogs of both LR and systemic transvenous infusion of rAAV2/8-Spc512-cMD1, paving the way for human clinical trials for either upper limb or whole body delivery in a manner potentially therapeutic for any DMD patients irrespective of their mutation genotype.

Methods
Vector design and production. Our vector contained a species-specific codon and mRNA sequence-optimized canine microdystrophin cDNA, that is, cMD1: ΔR4–23/ACT, that was placed under the control of muscle and cardiac synthetic Spc5.12 promoter. Two rAAV2/8-Spc5.12-cMD1 vector batches were produced using the S9/baculovirus expression vector system adapted for the rAAV8 (ref. 33). Briefly, S9 cells were cultured in serum-free insect cell medium (SF-900 II SFM medium, Life Technologies) at 27 °C using 501 of disposable bioreactors (Sartorius). After achieving the cell concentration of 1 million cells per ml, Rep2-Cap8 and ITR-Spc5.12-cMD1 baculoviruses were used for the co-transduction. Cells were left growing and then lysed to release vectors into the supernatant. The lysate was...
clarified on a 0.45 μm glass fibre frontal filter (Pall) and then purified using immunoaffinity chromatography column (AVB Sepharose HP, GE Healthcare). Finally, the vector was concentrated and formulated in Ringer-lactate solution (Baxter), sterile filtered, aliquoted and frozen at −70 °C. Several quality controls tests (physical titre, infectious titre, level of endotoxin, purity, sterility, pH, osmolality and in vitro functionality on GRMD myoblasts) were performed on each batch of vector before administration to dogs.

### Animals and vector delivery protocols

A total of 12 affected male GRMD dogs were injected with the rAAV2/8-Spc5.12-cMD1 vector, with 4 being injected via LR transvenous perfusion of one forelimb and 8 being injected via the IV route. In addition, 12 supplemental age matched male GRMD dogs were included as dysprosodic controls tests (physical titre, infectious titre, level of endotoxin, purity, sterility, pH, osmolality and in vitro functionality on GRMD myoblasts) were performed on each batch of vector before administration to dogs.

### Western blot analysis

For each muscle sample, total proteins were extracted from snap-frozen muscle samples using RIPA buffer (Tris 10 mM pH 7.5; NaCl 150 mM; EDTA 1 mM; NP40 1%; sodium deoxycholate 0.5%; SDS 0.1%) containing protease inhibitor cocktail (Sigma-Aldrich). Proteins extracts at 50 μg were loaded on a NuPAGE Novex 3–8% Tris Acetate gel and analysed using the NuPAGE large protein blotting kit (Thermo Fisher Scientific). Membranes were blocked in 5% skim milk, 1% NP40 (Sigma-Aldrich) in TBST (Tris-buffered saline, pH 7.5; Tween 20). The membranes were incubated with primary antibodies: anti-goat IgG HRP-conjugated antibody (1:2,000, Dako). Immunoblots were visualized by ECL Chemiluminescent analysis system (Thermo Fisher Scientific). All uncropped western blots included on the study are reported in Supplementary Fig. 11.

### Vector biodistribution analysis

Vector copy numbers in the muscular biopsies were determined in a blinded manner. Genomic DNA was extracted using Gentra Puregene kit (Qagen) and TissueLyser II (Qagen). Q-PCR analyses were conducted on a StepOne Plus (Life Technologies) using 50 ng of gDNA in duplicate. Reactions were performed in a final volume of 25 μl containing template DNA, Premix Ex Taq (Ozyme), 0.3 μl of ROX reference dye (Ozyme), 0.4 μmol l⁻¹ of each primer (Thermo Fisher Scientific) and 0.2 μmol l⁻¹ of Taqman probe (Thermo Fisher Scientific). Vector copy numbers were determined using primers and probe specifically designed to amplify the cMD1 transgene (forward: 5′-CAGCAACGATGCACCTACTCATCCT-3′; reverse: 5′-GGTGTGCTGTCGAGGCGGTGCT-3′; probe: 5′-FAM-CGCCAGCTTCAGCGCTGCTGCTGCTTGT-3′; probe: 5′-FAM-CCCGCCCAGCTTCAGGCTGCTGCGT-3′). Primers and probe designed to amplify the canine β-glucuronidase gene (forward: 5′-ACGGCTGATGTCACACACCA-3′; reverse: 5′-CCGACTGGTCCTCAGAGATGTC-3′; probe: 5′-FAM-CCTGCTGTCGACCGCGT-3′) were used to determine the endogenous gDNA copy numbers. For each sample, Ct values were compared with those of different dilutions of linearized standard plasmids (containing either the cMD1 expression cassette or the canine β-glucuronidase gene). The sensitivity of our test was 0.002 S.F. Statistical analyses were performed using a nonparametric Mann–Whitney test. A difference was considered to be significant at *P* < 0.05, **P** < 0.01 or ***P*** < 0.001.

### Immunostaining of cMD1-positive fibres

Muscles samples were snap-frozen in isopentane cooled in liquid nitrogen and stored at −70 °C until processing. Dystrophin-positive fibres were numbered in a blinded manner on serial transverse sections after immunohistochemical revelation of dystrophin using a mouse monoclonal anti-dystrophin antibody (Novocastra NCL-DYS-R, clone 3H4, 1:50, Leica). Goat anti-mouse biotinylated IgG (1:300, Dako) was used as secondary antibody, diluted in 5% dog serum in phosphate-buffered saline (PBS). The sections were then incubated with streptavidin/horseradish peroxidase (HRP) (1:300, Dako) and then revealed using 3,3′-diaminobenzidine (DAB, Dako). Although dystrophin-positive fibres in positive samples were scattered all along the muscle samples as individual or more often as clustered fibres, a minimum of 3 microscopic fields at intermediate magnification were randomly chosen to finally observe a minimum of 250 fibres (intraobserver variation coefficient was below 5%). All measurements were performed using Nikon’s NIS-Elements software (Nikon). Statistical analyses were performed using the nonparametric Mann–Whitney test. A difference was considered to be significant at *P* < 0.05, **P** < 0.01 or ***P*** < 0.001.

### Table 3 | Anti-cMD1-specific circulating IgG antibodies and anti-cMD1 specific IFN-γ secretion from PBMCs of GRMD dogs injected with rAAV2/8-Spc5.12-cMD1 by the LR or the IV route.

| Group | Dog | Circulating anti-cMD1 IgG | IFN-γ secretion by PBMCs with cMD1 peptides |
|-------|-----|---------------------------|------------------------------------------|
|       |     | M1 | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | 12 | 13 | 14 | 15 | 16 | 17 | 18 | 19 | 20 | 21 | 22 |
| LR    | 1 x 10⁷ vg kg⁻¹ | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| LR1   | - | NA | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| LR2   | - | NA | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| LR3   | - | NA | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| LR4   | - | NA | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
|        |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |
| IV-A  | 1 x 10⁷ vg kg⁻¹ | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| IV1   | - | NA | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| IV2   | - | NA | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| IV3   | - | NA | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| IV4   | - | NA | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| IV5   | - | NA | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| IV-B  | 2 x 10⁷ vg kg⁻¹ | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| IV6   | - | NA | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| IV7   | - | NA | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| IV8   | - | NA | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |

**Bef.**, before injection; **M**, month; *, detection of circulating anti-cMD1 IgG antibodies; **−−**, no detection of circulating anti-cMD1 IgG antibodies or no detection of IFN-γ secretion by PBMCs; **NA**, not applicable.
The document content is a research paper discussing the use of q-PCR and NMR imaging to study muscle disease progression in dogs. The main points include:

**Clinical follow-up.** The general clinical status of the systematically injected GRMD dogs was evaluated by a clinical grading done weekly after injection by the same doctor of veterinary medicine. Examination was blinded at the beginning of the study, up to when the difference between treated and untreated dogs became apparent. This evaluation includes 11 locomotion criteria and 6 items related to the general health status (including dysphagia, ptyalism, global activity and breathing).

**DNA sequence analysis of the Jagged1 gene.** Genomic DNA obtained from muscle samples of all untreated GRMD dogs and of the 8 GRMD dogs injected by the intravenous route with the rAAV2/8-Spc1.2-cMD1 vector was extracted using a specific torque measurement device built around interchangeable torque-sensing stimuli with a total duration of 1 ms were used and 30 s rest periods were waited between contractions. The maximal torque detected over all the elicited tetanic contractions was used to measure the maximal strength of the muscles (flexion and extension) and each side (flexed and extended). Each measurement session was performed all along the protocol. For each measurement, the maximal extension torque was expressed related to the animal weight in nm kg.

**Follow-up of the immune responses.** The analysis of anti-cMD1 IgG was performed in a blinded manner by a western-blot protocol. For this study protein extracts obtained from 293 cells not transfected or transfected by a pCMV-cMD1 plasmid were used instead of protein muscular extracts. Proteins were loaded on a NuPAGE Novex 3–8% Tris Acetate gel and analysed using the NuPAGE large protein blotting kit (Thermo Fisher Scientific) and then transferred to a Hybond ECL nitrocellulose membrane (Thermo Fisher Scientific). Membranes were blocked overnight and then incubated for 2 h at room temperature with sera from injected dogs (dilution 1:500). Peroxidase-conjugated rabbit anti-dog IgG antibody (1:5,000, Jackson ImmunoResearch) followed by enhanced chemiluminescence detection (Pierce) were used for detection. MANEX 1011C antibody (1:100; monoclonal antibody obtained from the MDA monoclonal antibody resource) and monoclonal antibody to alpha-actinin (1:2,000, Dako) were used as a positive control. Uncropped western blots are reported in Supplementary Figure 1.

**Strength assessment.** This assessment was performed in a blinded fashion, that is, the operator was not aware of the injected versus the noninjected forelimb, and using a specific torque measurement device built around interchangeable torque-sensing stimuli with a total duration of 1 ms were used and 30 s rest periods were waited between contractions. The maximal torque detected over all the elicited tetanic contractions was used to measure the maximal strength of the muscles (flexion and extension) and each side (flexed and extended).

**Histomorphological analysis.** Regeneration was evaluated after immunohistochemical detection of myofibers with an antibody specific of a developmental Myosin Heavy Chain isoform (1:20, Novocastra NCL-MHCd, clone RNMy29D2, Leica). Goat anti-mouse biotinylated IgG and DAB were used to reveal the signal as for the dystrophin staining. The percentage of labelled areas were measured after manual threshold on all muscle cross-sections (reproducibility coefficient: 17%).

**NMR imaging and spectroscopy analysis.** This assessment was done in a blinded fashion, that is, the operator was not aware of the injected versus the noninjected forelimb. NMR imaging was performed at 3-tesla in a Siemens Magnetom Trio (Siemens).

**vancomycin**

**Statistical analyses were performed using the nonparametric Kruskal–Wallis test and post hoc multiple comparison using Dunn’s test. A difference was considered to be significant at \( *P < 0.05 \), \( **P < 0.01 \) or \( ***P < 0.001 \).**
and then incubated with heat-inactivated serum diluted from 1:3 to 1:7,290 (or more diluted if necessary) for 1 h at 37°C. After three washes, purified antibodies specific for IgG or IgM (Sigma Aldrich) were added and incubated for 1 h at room temperature. After incubation the plates were washed three times with wash buffer. HRP-conjugated sheep anti-mouse antibody (GE Healthcare) was added and incubated for 1 h at room temperature. Last, plates were washed three times with wash buffer and incubated with tetramethylbenzone substrate solution (BD Biosciences) for 30 min in the dark. The reaction was stopped with H2SO4 solution and measurements were made at 450 nm. The results are expressed as arbitrary optical density (OD) units using a colourimetric amplification system based on peroxidase. The AAV-specific signal was reported as the OD from AAV-coated ELISA plate per well divided by the OD obtained on control protein ELISA, a nonspecific signal (OD AAV-OD nonspecific signal).

The levels of circulating anti-AAV NAF were determined as follows. On day 1, 48-well plates were seeded with 5 × 10^5 HuH7 cells per well for 24 h. On day 2, recombinant AAV8-CMV-Luciferase (AAV-CMV-Luc) was diluted in Dulbecco’s modified Eagle’s medium (Thermo Fisher Scientific) supplemented with 10% fetal serum and diluted from 1:3 to 1:7,290 (or more diluted if necessary) for 1 h at 37°C. After incubation the plates were washed three times with wash buffer. HRP-conjugated sheep anti-mouse antibody (GE Healthcare) was added and incubated for 1 h at room temperature. Plates were washed three times with wash buffer. After incubation the plates were washed three times with wash buffer. HRP-conjugated sheep anti-mouse antibody (GE Healthcare) was added and incubated for 1 h at room temperature. Last, plates were washed three times with wash buffer and incubated with tetramethylbenzone substrate solution (BD Biosciences) for 30 min in the dark. The reaction was stopped with H2SO4 solution and measurements were made at 450 nm. The results are expressed as arbitrary optical density (OD) units using a colourimetric amplification system based on peroxidase. The AAV-specific signal was reported as the OD from AAV-coated ELISA plate per well divided by the OD obtained on control protein ELISA, a nonspecific signal (OD AAV-OD nonspecific signal).

The neutralizing titre was reported as the highest dilution of serum that caused a 50% reduction in the relative luciferase activity compared with the negative control and was determined in a similar manner to that described above except that a 1:3,000 to 1:1,000,000 dilution of serum was used. Neutralizing titre were based on the number of spots formed under stimulation of cells infected with AAV-CMV-Luciferase (AAV-CMV-Luc). The neutralizing titre was reported as the highest dilution of serum that caused a 50% reduction in the relative luciferase activity compared with the negative control and was determined in a similar manner to that described above except that a 1:3,000 to 1:1,000,000 dilution of serum was used. Neutralizing titre were based on the number of spots formed under stimulation of cells infected with AAV-CMV-Luciferase (AAV-CMV-Luc).

Assessment of cardiac function. Cardiac function of GRMD dogs injected with rAAV-OD/C2 was measured using a 2D echocardiography with a Siemens Acuson Sequoia C256 ultrasound unit equipped with 5–7.5 and 2–5 MHz phased-array transducers. Radial thicknesses were measured and left ventricular fractional shortening and ejection fraction were calculated. Radial thicknesses were measured and left ventricular fractional shortening and ejection fraction were calculated. Radial thicknesses were measured and left ventricular fractional shortening and ejection fraction were calculated.

Data availability. The data that support the findings of this study are available from the corresponding authors on reasonable request.

References

1. Koenig, M. et al. Complete cloning of the Duchenne muscular dystrophy (DMD) cDNA and preliminary genomic organization of the DMD gene in normal and affected individuals. Cell 50, 509–517 (1987).

2. Bonilla, E. et al. Duchenne muscular dystrophy: deficiency of dystrophin at the muscle cell surface. Cell 54, 447–452 (1988).

3. Judge, L. M., Haraguchi, M. & Chamberlain, J. S. Dissecting the signaling and mechanical functions of the dystrophin-glycoprotein complex. J. Cell Biol. 119, 1537–1546 (2006).

4. Eagle, M. et al. Managing Duchenne muscular dystrophy—the additive effect of spinal surgery and home nocturnal ventilation in improving survival. Neuromuscul. Disord. 17, 470–475 (2007).

5. Ishikawa, Y. et al. Duchenne muscular dystrophy: survival by cardio-pulmonary interventions. Neuromuscul. Disord. 21, 47–51 (2011).

6. Xiao, X. Li, J. & Samulski, R. J. Efficient long-term gene transfer into muscle tissue of immunocompetent mice by adeno-associated virus vector. J. Virol. 70, 8098–8108 (1996).

7. Wang, Z. et al. Adeno-associated virus serotype 8 efficiently delivers genes to muscle and heart. Nat. Biotechnol. 23, 321–328 (2005).

8. Ribeiro, J. M., Gregorevic, P. & Chamberlain, J. S. Gene therapy strategies for Duchenne muscular dystrophy utilizing recombinant adeno-associated virus vectors. Mol. Ther. 13, 241–249 (2006).

9. Pack, C. A. et al. Recombinant adeno-associated virus serotype 9 leads to preferential cardiac transduction in vivo. Circ. Res. 99, e3–e9 (2006).

10. Zhang, C. et al. Safety and efficacy of regional intravenous (r.i.) versus intramuscular (i.m.) delivery of rAAV1 to rAAV8 in nonhuman primate skeletal muscle. Mol. Ther. 16, 1291–1299 (2008).

11. Bonilla, E. et al. Long-term pharmacologically regulated expression of erythropoietin in primates following AAV-mediated gene transfer. Blood 105, 1424–1430 (2005).

12. Jiang, H. et al. Evidence of multitype factor IX expression by AAV-mediated gene transfer to skeletal muscle in an adult with severe hemophilia B. Mol. Ther. 14, 452–455 (2006).

13. Harper, S. Q. et al. Modular flexibility of dystrophin: implications for gene therapy of Duchenne muscular dystrophy. Nat. Med. 8, 253–261 (2002).

14. Athanasopoulos, T., Graham, I. R., Foster, H. & Dickson, G. Recombinant adeno-associated viral (rAAV) vectors as therapeutic tools for Duchenne muscular dystrophy (DMD). Gene Ther. 11(suppl. 1): S109–S121 (2004).

15. Muntoni, F., Torelli, S. & Ferlini, A. Dystrophin and mutations: one gene, several proteins, multiple phenotypes. Lancet Neurol. 2, 731–740 (2003).

16. Wang, B., Li, J. & Xiao, X. Adeno-associated virus vector carrying human minidystrophin genes effectively ameliorates muscular dystrophy in mdx mouse model. Proc. Natl Acad. Sci. USA 97, 13714–13719 (2000).

17. Yoshimura, M. et al. AAV vector-mediated microdystrophin expression in a relatively small percentage of myofibers improves the mdx phenotype. Mol. Ther. 10, 821–828 (2004).

18. Gregorevic, P. et al. rAAV6-microdystrophin prevents muscle damage and extends lifespan in severely dystrophic mice. Nat. Med. 12, 787–789 (2006).

19. Foster, H. et al. Codon and mRNA sequence optimization of microdystrophin transgenes improves expression and physiological outcome in dystrophic mdx mice following AAV8/g gene transfer. Mol. Ther. 16, 1825–1832 (2008).

20. Li, X., Eastman, E. M., Schwartz, R. J. & Draghia-Akli, R. Synthetic muscle promoters: activities exceeding naturally occurring regulatory sequences. Nat. Biotechnol. 17, 241–245 (1999).

21. Koo, T. et al. Delivery of AAV2/9-microdystrophin genes incorporating helix 1 of the coiled-coil motif in the C-terminal domain of dystrophin improves muscle pathology and restores the levels of alpha-1-syntrophin and alpha-dystrobrevin in skeletal muscles of mdx mice. Hum. Gene Ther. 22, 1379–1388 (2011).

22. Athanasopoulos, T., Foster, H., Foster, K. & Dickson, G. Codon optimization of the microdystrophin gene for Duchenne muscular dystrophy gene therapy. Methods Mol. Biol. 709, 21–37 (2011).

23. Koo, T. et al. Long-term parental adeno-associated virus-microdystrophin expression in the dystrophic CXM'Dog. J. Gene Med. 13, 497–506 (2011).

24. Kornegay, J. N. et al. Canine models of Duchenne muscular dystrophy and their use in therapeutic strategies. Mamm. Genome 23, 85–108 (2012).

25. McGreevy, J. W., Hakim, C. H., McIntosh, M. A. & Duan, D. Animal models of Duchenne muscular dystrophy: from basic mechanisms to gene therapy. Dis. Model. Mech. 8, 195–213 (2015).

26. Wang, Z. et al. Sustained AAV-mediated dystrophin expression in a canine model of Duchenne muscular dystrophy with a brief course of immunosuppression. Mol. Ther. 15, 1160–1166 (2007).

27. Wang, Z. et al. Successful regional delivery and long-term expression of a dystrophin gene in canine muscular dystrophy: a preclinical model for human therapies. Mol. Ther. 20, 1501–1507 (2012).

28. Shin, J. H. et al. A simplified immune suppression scheme leads to persistent micro-dystrophin expression in Duchenne muscular dystrophy dogs. Hum. Gene Ther. 23, 202–209 (2012).
30. Shin, J. H. et al. Microdystrophin ameliorates muscular dystrophy in the canine model of duchenne muscular dystrophy. Mol. Ther. 21, 750–757 (2013).
31. Wang, Y. et al. Antihicalete, L., Nahid, M. A. & Gao, G. The potential of adenovirus-associated viral vectors for gene delivery to muscle tissue. Expert Opin. Drug Deliv. 11, 345–364 (2014).
32. Hayashita-Kinoh, H. et al. Intramuscular rAAV-mediated microdystrophin gene therapy improves canine X-linked muscular dystrophy and may induce immune tolerance. Mol. Ther. 23, 627–637 (2015).
33. Le Guiner, C. et al. Forelimb treatment in a large cohort of dystrophic dogs supports delivery of a recombinant AAV for exon skipping in Duchenne patients. Mol. Ther. 22, 1923–1935 (2014).
34. Fan, Z. et al. Safety and feasibility of high-pressure transvenous limb perfusion with 0.9% saline in human muscular dystrophy. Mol. Ther. 20, 456–461 (2012).
35. Fan, Z. et al. High-pressure transvenous perfusion of the upper extremity in human muscular dystrophy: a safety study with 0.9% saline. Hum. Gene Ther. 26, 614–621 (2015).
36. Nguyen, F., Cherel, Y., Guigand, L., Goubault-Leroux, I. & Wyers, M. Muscle lesions associated with dystrophin deficiency in neonatal golden retriever puppies. J. Comp. Pathol. 126, 100–108 (2002).
37. Dubowitz, V., Wary, C., Oldfors, A. in Muscle Biopsy: A Practical Approach 4th edn. 250–275 (Saunders Co Ltd, Elsevier Health Sciences, 2013).
38. Thibaud, J. L. et al. Comprehensive longitudinal characterization of canine muscular dystrophy by serial NMR imaging of GRMD dogs. Neuromuscul. Disorders 12, 788–796 (2009).
39. Dubrov, A. et al. Longitudinal ambulatory measurements of gait abnormality in dystrophin-deficient dogs. BMC Musculoskelet. Disord. 12, 75 (2011).
40. Arechavala-Gomeza, V. et al. Characterization of dystrophin deficient rats: a new model for Duchenne muscular dystrophy. PLoS ONE 9, e103071 (2014).
41. Vieira, N. M. et al. Isolated muscle function recovery in golden retriever muscular dystrophy after AAV1-U7 exon skipping. Mol. Ther. 20, 2120–2133 (2012).
42. Pang, D. et al. Characterization of dystrophin deficient rats: a new model for Duchenne muscular dystrophy. PLoS ONE 9, e103071 (2014).
43. Kornegay, J. N. et al. Widespread muscle expression of an AAV9 human mini-dystrophin vector after intravenous injection in neonatal dystrophin-deficient dogs. Mol. Ther. 18, 1501–1508 (2010).
44. Day, M. J. Immune system development in the dog and cat. J. Comp. Pathol. 137, 1–30 (2007).
45. Yue, Y. et al. Safe and bodywide muscle transduction in young adult Duchenne muscular dystrophy dogs with adeno-associated virus. Hum. Mol. Genet. 24, 5880–5890 (2015).
46. Fehlings, P. J. Overview of immune system development in the dog: comparison with humans. Hum. Exp. Toxicol. 21, 487–492 (2002).
47. Haurnigt, V. et al. Safety of AAV factor IX peripheral transvenous gene delivery to muscle in hemophilia B dogs. Mol. Ther. 18, 1318–1329 (2010).
48. Toromanoff, A. et al. Lack of immunotoxicity after regional intravenous (RI) delivery of rAAV to nonhuman primate skeletal muscle. Mol. Ther. 18, 151–160 (2010).
49. Arruda, V. R. et al. Peripheral transvenular delivery of adeno-associated viral vectors to skeletal muscle as a novel therapy for hemophilia B. Blood 115, 4678–4688 (2010).
50. Bourgourisse, F. et al. Phenotypic correction of alpha-sarcoglycan deficiency by intraarterial injection of a muscle-specific serotype 1 rAAV vector. Mol. Ther. 15, 53–61 (2007).
51. Aremhever-Gomez, V. et al. Revertant fibres and dystrophin traces in Duchenne muscular dystrophy: implication for clinical trials. Neuromuscul. Disorders 20, 295–301 (2010).
52. Halbert, C. L., Metger, M. J., Lam, S. L. & Miller, A. D. Capsid-expressing DNA in AAV vectors and its elimination by use of an oversize capsid gene for vector production. Gene Ther. 18, 411–417 (2011).
53. Wang, Z. et al. Elimination of contaminating cap genes in AAV vector virions reduces immune responses and improves transgene expression in a canine therapy model. Gene Ther. 21, 363–370 (2014).
54. Revertant fibres and dystrophin traces in Duchenne muscular dystrophy: implication for clinical trials. Neuromuscul. Disorders 20, 295–301 (2010).
55. Halbert, C. L., Metger, M. J., Lam, S. L. & Miller, A. D. Capsid-expressing DNA in AAV vectors and its elimination by use of an oversize capsid gene for vector production. Gene Ther. 18, 411–417 (2011).
56. Wang, Z. et al. Elimination of contaminating cap genes in AAV vector virions reduces immune responses and improves transgene expression in a canine therapy model. Gene Ther. 21, 363–370 (2014).
57. Nathwani, A. C. et al. Long-term safety and efficacy of factor IX gene therapy in hemophilia B. N. Engl. J. Med. 371, 1994–2004 (2014).
58. Chicoine, L. G. et al. Plasmapheresis eliminates the negative impact of AAV antibodies on microdystrophin gene expression following vascular delivery. Mol. Ther. 22, 338–347 (2014).
59. Bartlett, R. J. et al. In vivo targeted repair of a point mutation in the canine dystrophin gene by a chimeric RNA/DNA oligonucleotide. Nat. Biotechnol. 18, 1515–1522 (2000).
60. Frayse, B. et al. Gait characterization in golden retriever muscular dystrophy dogs using linear discriminant analysis. BMC Musculoskelet. Disord. 18, 153 (2017).
61. Thomas, W. P. et al. Recommendations for standards in transthoracic two-dimensional echocardiography in the dog and cat. Echocardiography Committee of the Specialty of Cardiology, American College of Veterinary Internal Medicine. J. Vet. Intern. Med. 7, 247–252 (1993).

Acknowledgements
We pay tribute to Y. Cherel, who passed away during the course of this study, for his valuable contribution. We also thank F. Barnay Toutain, M. Hebben and C. Le Bec for their work to provide us with rAAV vectors. We thank C. Joumer and all the personnel of the Bouisson Center for Gene Therapy (ONIRIS, Atlantic Gene Therapies, Nantes, France) for the handling and care of the GRMD dog colony. We thank H. Goubin and L. Guigand (Atlantic Gene Therapies, INRA UMR 703, Nantes, France), C. Couzinié, C. Domenger, C. Gazaille, M. Guilbaud, N. Jaulin, C. Lebetion and C. Vandamme (Atlantic Gene Therapies, INSERM UMR 1089, Nantes, France), E. Beril, F. Border, Simon Fradin, E. Giambelluco, D. Goncalves-Dufour, C. Luc, S. Potier, S. Rundwasser and G. Sirantoine (Genethon, Evry, France) and Y. Fromes, A. Moraux and C. Wary (Institute of Myology, Paris, France) for their technical assistance. We thank the MDA Monoclonal Antibody Resource for providing the MANEX 1011C antibody. Finally, we also thank S. Roques for its valuable contribution during the implementation of this study. This project was supported by AFM-Téléthon (Association Française contre les Myopathies), the MDUK (Muscular Dystrophy UK), the French Agence Nationale pour la Recherche (ANR grant 14-CE15-001-01), INSERM, INRA, the University of Nantes and the University Hospital of Nantes.

Author contributions
C.L.G., L.S., F.Ma., T.V., P.M. and G.D. designed the study and reviewed some or all the primary data. T.K., A.M., S.Ma., T.A. and G.D. designed and constructed the vector. B.F., S.Me., J.-Y.D., I.B., S.R., I.T., K.W., S.R. and J.-Y.H. performed and reviewed the clinical and physiological evaluations. J.-L.T., R.M. and P.C. performed and reviewed the RMN and spectroscopy evaluations. M.A., V.F. and C.L.G. performed and reviewed the molecular and biochemical analyses. T.L., M.Du., C.G. and B.G. performed and reviewed the histopathological and immunochimistry analyses. M.De., I.L.D., P.V., C.M., F.Ma. and O.A. performed and reviewed the immunological assays. C.L.G., T.A., F.Ma. and P.M. wrote the manuscript. All authors reviewed the manuscript.

Additional information
Supplementary Information accompanies this paper at http://www.nature.com/ naturecommunications
Competing interests: C.L.G., T.V., P.M. and G.D. have filed a patent application for systemic treatment of dystrophic pathologies (PCT/EP2015/064703, dated 29 June 2015). The remaining authors declare no competing financial interests.
Reprints and permission information is available online at http://npg.nature.com/ reprintsandpermissions/
How to cite this article: Le Guiner, C. et al. Long-term microdystrophin gene therapy is effective in a canine model of Duchenne muscular dystrophy. Nat. Commun. 8, 16105 doi: 10.1038/ncomms16105 (2017).
Publisher’s note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.